Home/Filings/4/0001780660-25-000002
4//SEC Filing

LO FRANCIS 4

Accession 0001780660-25-000002

CIK 0001478320other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 7:06 PM ET

Size

17.8 KB

Accession

0001780660-25-000002

Insider Transaction Report

Form 4
Period: 2025-12-15
LO FRANCIS
Chief People Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-15$7.80/sh+37,750$294,450370,596 total
  • Exercise/Conversion

    Common Stock

    2025-12-15$8.46/sh+19,423$164,319390,019 total
  • Exercise/Conversion

    Common Stock

    2025-12-15$3.99/sh+39,849$158,998429,868 total
  • Sale

    Common Stock

    2025-12-15$15.57/sh113,890$1,773,267315,978 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-12-1537,750113,250 total
    Exercise: $7.80Exp: 2029-05-06Common Stock (37,750 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-12-1519,423109,176 total
    Exercise: $8.46Exp: 2033-03-06Common Stock (19,423 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-12-1539,849110,175 total
    Exercise: $3.99Exp: 2034-03-04Common Stock (39,849 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    2,500
Footnotes (5)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
  • [F2]The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.37 to $16.03, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  • [F3]The option is fully vested and exercisable.
  • [F4]The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  • [F5]The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Issuer

Adaptive Biotechnologies Corp

CIK 0001478320

Entity typeother

Related Parties

1
  • filerCIK 0001780660

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 7:06 PM ET
Size
17.8 KB